



03-17-04

1614
PHA 2004 (3167/12/US)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of John P. McKearn et al. Art Unit 1614
Serial No. 09/843,132
Filed April 25, 2001
Confirmation No. 8349
For ANTINEOPLASTIC COMBINATION THERAPY IN THE TREATMENT OF
CANCER

March 16, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

In preparation of this Supplemental Information Disclosure Statement, Applicants determined that approximately 1,000 references were cited in the application. In an effort to reduce the burden on the Office, each reference was briefly reviewed by an attorney. This review eliminated any reference that was determined to be irrelevant or merely cumulative. If the Office would like a copy of the eliminated references, they can be provided at the Office's request.

* A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR §1.17(p) for submission of this Supplemental Information Disclosure Statement. The Commissioner

03/18/2004 HDEMESS1 00000018 09843132


01 FC:1806

180.00 DP

PHA 2004 (3167/12/US)
PATENT

is hereby authorized to charge any under payment or credit any
over payment to Deposit Account No. 19-1345.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

KJD/msc
*Enclosures

Express Mail Label No. EV 416453101 US

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Complete if Known

Application Number	09/843,132
Filing Date	April 25, 2001
Confirmation Number	8349
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Rebecca Cook

Sheet 1 of 2 Attorney Docket No. PHA 2004 (3167/12/US)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
44.	6,077,850			Carter et al.	06-20-2000
45.	6,087,392			Reiter	07-11-2000
46.	6,110,964			Robinson	08-29-2000
47.	6,114,361			Robinson et al.	09-05-2000
48.	6,156,798			Reiter	12-05-2000
49.	6,214,870	B1		McClure et al.	04-10-2001
50.	6,277,878	B1		Nakao et al.	08-21-2001
51.	6,294,558	B1		Ando et al.	09-25-2001
52.	6,303,628	B1		Nakao et al.	10-16-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴			
53.	EP	1 081 137	A1	Pfizer Products Inc.	03-07-2001	
54.	EP	1 088 550	A1	Pfizer Products Inc.	04-04-2001	

Examiner Signature	Date Considered
--------------------	-----------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Complete if Known

Application Number	09/843,132
Filing Date	April 25, 2001
Confirmation Number	8349
First Named Inventor	John P. McKearn et al.
Group Art Unit	1614
Examiner Name	Rebecca Cook

Sheet **2** of **2** Attorney Docket No. **PHA 2004 (3167/12/US)**

55.	EP	1 104 759	A1	Pfizer Products Inc.	06-06-2001	
56.	EP	1 104 760	A1	Pfizer Products Inc.	06-06-2001	
57.	EP	1 134 215	A1	Pfizer Products Inc.	09-19-2001	
58.	EP	1 138 680	A1	Pfizer Products Inc.	10-04-2001	
59.	WO	97/20824	A1	Agouron Pharmaceuticals, Inc.	06-12-1997	
60.	WO	98/03516	A1	Pfizer Inc.	01-29-1998	
61.	WO	98/30566	A1	Pfizer Inc.	07-16-1998	
62.	WO	98/47890	A1	G.D. Searle & Co.	10-29-1998	
63.	WO	99/21583	A1	Warner-Lambert Company	05-06-1999	
64.	WO	00/09485	A1	Pfizer Products Inc.	02-24-2000	
65.	WO	00/09492	A1	Pfizer Products Inc.	02-24-2000	
66.	WO	00/73294	A2	Pfizer Products Inc.	12-07-2000	
67.	WO	01/12611	A1	Pfizer Products Inc.	02-22-2001	
68.	WO	01/40216	A1	Pfizer Products Inc.	06-07-2001	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	69.	TRIFAN, O.C., et al., Cyclooxygenase-2 Inhibition with Celecoxib Enhances Antitumor Efficacy and Reduces Diarrhea Side Effect of CPT-11, Cancer Research, Oct. 15, 2002, pp. 5778-84, Vol. 62, No. 20	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



FEE TRANSMITTAL

Application Number 09/843,132
Filing Date April 25, 2001
Confirmation No. 8349
Inventor(s) John P. McKearn et al.
Attorney Docket Number PHA 2004 (3167/12/US)

Art Unit 1614

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.
- The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 to Deposit Account No. 19-1345.
- Applicant claims small entity status.

2. Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

FEE CALCULATION

1. BASIC FILING FEE Subtotal (1) \$ _____
(Type: _____)

2. EXTRA CLAIM FEES Subtotal (2) \$ _____
Total Claims _____
Independent Claims _____
Multiple Dependent Claims _____

3. ADDITIONAL FEES Subtotal (3) \$ 180.00
 Surcharge - late filing fee or oath
 Surcharge - late provisional filing fee or cover sheet
 Extension for reply within _____ month
 Notice of Appeal
 Filing a Brief in Support of an appeal
 Request for ex parte Reexamination
 Petitions to the Commissioner
 Submission of Information Disclosure Statement
 Recording each patent assignment per property
 Request for Continued Examination
 Other: _____

TOTAL AMOUNT OF PAYMENT \$ 180.00

Kathryn J. Doty, Reg. No. 40,593

March 16, 2004

Date

KJD/CDS/cms

Express Mail Label No. EV 416453101 US